ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
Oxford University Press
2017
|
| _version_ | 1797087581966434304 |
|---|---|
| author | Morgensztern, D Ong, TJ Dols, MC Aix, SP Postmus, PE Lewanski, C Bennouna, J Fischer, JR Vidal, OJ Stewart, DJ Fasola, G Ardizoni, A Weaver, J Wolfsteiner, M Talbot, D Govindan, R |
| author_facet | Morgensztern, D Ong, TJ Dols, MC Aix, SP Postmus, PE Lewanski, C Bennouna, J Fischer, JR Vidal, OJ Stewart, DJ Fasola, G Ardizoni, A Weaver, J Wolfsteiner, M Talbot, D Govindan, R |
| author_sort | Morgensztern, D |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T02:37:41Z |
| format | Conference item |
| id | oxford-uuid:a956854d-1faa-47bf-aa60-bcc314b711d6 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T02:37:41Z |
| publishDate | 2017 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:a956854d-1faa-47bf-aa60-bcc314b711d62022-03-27T03:07:53ZABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:a956854d-1faa-47bf-aa60-bcc314b711d6Symplectic Elements at OxfordOxford University Press2017Morgensztern, DOng, TJDols, MCAix, SPPostmus, PELewanski, CBennouna, JFischer, JRVidal, OJStewart, DJFasola, GArdizoni, AWeaver, JWolfsteiner, MTalbot, DGovindan, R |
| spellingShingle | Morgensztern, D Ong, TJ Dols, MC Aix, SP Postmus, PE Lewanski, C Bennouna, J Fischer, JR Vidal, OJ Stewart, DJ Fasola, G Ardizoni, A Weaver, J Wolfsteiner, M Talbot, D Govindan, R ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) |
| title | ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) |
| title_full | ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) |
| title_fullStr | ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) |
| title_full_unstemmed | ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) |
| title_short | ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) |
| title_sort | abound 2l nab paclitaxel nab p cc 486 or durvalumab in previously treated patients with advanced non small cell lung cancer nsclc |
| work_keys_str_mv | AT morgenszternd abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT ongtj abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT dolsmc abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT aixsp abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT postmuspe abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT lewanskic abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT bennounaj abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT fischerjr abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT vidaloj abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT stewartdj abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT fasolag abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT ardizonia abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT weaverj abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT wolfsteinerm abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT talbotd abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc AT govindanr abound2lnabpaclitaxelnabpcc486ordurvalumabinpreviouslytreatedpatientswithadvancednonsmallcelllungcancernsclc |